Revolutionizing Prostate Cancer Diagnosis: The Future of Genetic Screening
Prostate cancer remains the second most common cause of cancer deaths in men in the UK, sparking a continuous search for more reliable screening methods. A breakthrough study suggests that a novel at-home spit test, based on polygenic risk scores (PRS), offers a more accurate prediction of prostate cancer risk compared to traditional blood tests. This game-changer could help identify aggressive cancers earlier, sparing many of unnecessary treatments.
Understanding the Polygenic Risk Score
The PRS spit test evaluates 130 genetic variants tied to prostate cancer. The study, published in the New England Journal of Medicine, found that men with the highest 10% of PRS scores were more likely to have cancer upon further testing than those with high levels of prostate-specific antigen (PSA) through traditional blood tests. The spit test’s ability to pinpoint aggressive cancers more effectively stands at 55.1%, compared to 35.5% identified by PSA tests.
Improving Screening with Genetic Insights
Prof Ros Eeles, head of the research team at the Institute of Cancer Research, London, highlights that this PRS test is not only a breakthrough for men of European heritage but also shows promise for other ethnicities with tailored versions. It could become a crucial tool for doctors, helping to determine who might benefit from aggressive treatments and potentially influencing future screening guidelines.
Taking Action: A Push for Inclusive Testing
Following Chris Hoy’s heartfelt appeal for tests available to younger men and black men—twice as likely to be diagnosed with prostate cancer than white men—the NHS may reconsider screening policies. Health secretary Wes Streeting is inclined to support a risk-based screening program if supported by evidence.
The Hurdles of PSA Testing
Current PSA tests can falsely indicate cancer in three out of four men, leading to unnecessary procedures with side effects like urinary incontinence and sexual dysfunction. Adjusting screening practices with PRS could reduce these false positives by offering a more targeted approach, reducing patient anxiety and the strain on healthcare systems.
Enhanced Screening Protocol: A Possibility?
As research progresses, experts like Prof Kristian Helin emphasize the urgent need for better screening tests aside from PSA. A PRS-based approach could bridge this gap, prioritizing early detection of aggressive cancers while sparing low-risk individuals from invasive testing.
Frequently Asked Questions
What is a polygenic risk score?
A measure used to estimate an individual’s predisposition to certain diseases based on various genetic markers.
How accurate is the new spit test compared to the PSA test?
The spit test identifies aggressive cancers in 55.1% of cases, higher than the 35.5% accuracy rate of the PSA test.
Who can benefit from this new test?
Moving forward, it’s particularly beneficial for those with a genetic predisposition or a family history of prostate cancer, as well as for populations previously underrepresented in genetic studies.
Pro Tips for Men’s Health
Did you know? Engaging with genetic counseling can provide comprehensive insights tailored to your personal and familial health history, informing better screening decisions.
Join the Conversation
Your thoughts and experiences are valuable. Join the discussion by commenting below or exploring more articles on the challenges and innovations in prostate cancer diagnosis. Stay informed by subscribing to our health newsletter!
Related reading